Page last updated: 2024-11-13
callipeltin a
Description
callipeltin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
callipeltin A : A 10-membered cyclodepsipeptide containing four amino acids in the L- configuration, Ala, Leu, Thr (2 residues); one (Arg) in the D-configuration; two N-methyl amino acids, N-MeAla and N-MeGln; a methoxy tyrosine, a 3, 4-dimethyl-L-glutamine, and a 4-amino-7-guanidino-2,3 dihydroxypentanoic acid (AGDHE), formally derived from L-Arg. It is obtained from the shallow water sponge Callipelta and has been found to show activity against HIV virus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (3)
| Synonym |
|---|
| callipeltin a |
| CHEBI:65556 |
| Q27134009 |
Research Excerpts
Overview
Callipeltin A is a cyclic depsidecapeptide isolated from the marine sponges Callipelta sp. It inhibits the cardiac sodium/calcium exchanger and is therefore of interest as a regulator of myocardial contractility.
| Excerpt | Reference | Relevance |
|---|
| "Callipeltin A is a cyclic depsidecapeptide isolated from the marine sponges Callipelta sp. " | ( Callipeltin A: sodium ionophore effect and tension development in vascular smooth muscle.
Cargnelli, G; Ceolotto, G; D'Auria, MV; Luciani, S; Papparella, I; Semplicini, A; Trevisi, L; Zampella, A, 2004) | 3.21 |
| "Callipeltin A is a novel cyclic depsipeptide that selectively inhibits the cardiac sodium/calcium exchanger and is therefore of interest as a regulator of myocardial contractility. " | ( Stereoselective synthesis of four stereoisomers of beta-methoxytyrosine, a component of callipeltin A.
Carroll, PJ; Hansen, DB; Joullié, MM; Wan, X, 2005) | 1.99 |
Actions
Roles (3)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| anti-HIV-1 agent | An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus. |
| antifungal agent | An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
| Class | Description |
|---|
| guanidines | Any organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| cyclodepsipeptide | A depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring. |
| lactone | Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. |
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (84.62) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.30 (24.57) | | Research Supply Index | 2.64 (2.92) | | Research Growth Index | 4.94 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |